Unlock instant, AI-driven research and patent intelligence for your innovation.

Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same

An erythropoietin, mixture technology, applied in the field of erythropoietin (EPO), can solve problems such as reducing liver clearance rate and increasing circulation time

Inactive Publication Date: 2012-10-03
RATIOPHARM GHBH (DE)
View PDF24 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In this context, Rush et al. (Anal. Chem. (Analytical Chemistry) 67 (1995), 1442-1452) describe the O-acetylation of sialic acid residues of erythropoietin and its effect on increasing circulation time, and showed that a high degree of O-acetylation of sialic acid residues increases circulation time by reducing hepatic clearance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same
  • Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same
  • Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] Example 1: Capture of EPO and reduction of possible contaminants by affinity chromatography using Blue Sepharose 6FF (Blue Sepharose 6FF)

[0095] Blue Sepharose 6FF is an agarose resin covalently attached to the dye Cibacron Blue and used to preferentially bind EPO in the presence of contaminants contained in the fermentation harvest. The product stream was first purified by affinity chromatography as described in Table 2.

[0096] Table 2: Parameters used to perform Blue Sepharose chromatography

[0097]

[0098] The column was packed with Blue Sepharose 6FF resin. After packing, the columns were qualified for theoretical plates and asymmetry factors. The column was sterilized with 0.5 M NaOH for 1 h and then washed with water for injection (WFI). Before loading, the column was equilibrated with 20 mM Tris.HCl, 1.5M NaCl, pH 7.5, then with 20 mM Tris.HCl, pH 7.5. The sample was loaded onto the column and the column was washed with 20 mM Tris.HCl, pH 7.5. Sampl...

Embodiment 2

[0101] Example 2: Concentration of EPO by Diafiltration

[0102] The eluate was concentrated by ultrafiltration and diafiltration was performed on a tangential flow filtration device using a 10 kDa cut-off membrane; see Table 3.

[0103] Table 3: Parameters used to perform diafiltration

[0104]

[0105] Perform a normal water flux assay (NWP) before using the filter unit. The filter unit was sterilized with 1M NaOH for at least 1 h, then washed with WFI. After washing, filter devices were equilibrated with 20 mM Tris-HCl, pH 7.0. The sample is then loaded and filtered at a transmembrane pressure not to exceed 1 bar. Diafiltration was terminated when the conductivity of the permeate was below 2.5 mS / cm.

Embodiment 3

[0106] Example 3: Enrichment of acidic isoforms of EPO and further removal of contaminants by anion exchange chromatography using Q-Sepharose HP

[0107] Anion exchange chromatography using Q-Sepharose HP resin was used to enrich for the acidic isoforms of EPO, further removing contaminants (e.g. DNA, HCP) and eliminating any dye ligands that might have leached from the first column. Furthermore, anion exchange chromatography is an effective step for the removal of adventitious viruses. Therefore, the leachate was processed by anion exchange chromatography as described in Table 4, followed by 0.2 μm filtration of the Q eluate fraction and fraction pool.

[0108] Table 4: Parameters used to perform anion exchange chromatography

[0109]

[0110] The column was packed with Q-Sepharose HP resin. After packing, the columns were qualified for theoretical plates and asymmetry factors. The column was rinsed with WFI and then sanitized with 1M NaOH for 1 hour. After sanitization,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

A procedure for the production of erythropoietin (EPO), in particular recombinant human EPO (rhEPO) with a defined composition of glycoforms in a highly pure form, i.e., with a high amount of O-glycosylated EPO isoforms is provided.

Description

technical field [0001] The present invention relates to a process for the production of erythropoietin (EPO), in particular recombinant human EPO (rhEPO) in highly pure form with a defined glycoform composition, ie with a large number of O-glycosylated EPO isoforms. This is achieved by using a specific combination of chromatographic steps. Background technique [0002] Erythropoietin is the main hormone that regulates the proliferation and differentiation of erythroid progenitor cells and maintains physiological levels of circulating erythrocytes. In the fetus, EPO is mainly produced in the liver, after birth, about 90% of its production switches to the kidneys. When EPO levels fall due to chronic or acute renal failure, EPO must be administered externally to prevent anemia. Since the discovery of the EPO gene and its expression in rodent cells, therapeutically active human erythropoietin has become available. Native human erythropoietin is encoded by a gene located at 7q...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/505C07K1/16
CPCC07K14/505A61K38/00A61P7/06
Inventor 沃尔特·因德雷尔斯特凡·阿诺德
Owner RATIOPHARM GHBH (DE)